Blood Res 2021; 56(S1):
Published online April 30, 2021
https://doi.org/10.5045/br.2021.2020332
© The Korean Society of Hematology
Correspondence to : Moon-Woo Seong, M.D., Ph.D.
Department of Laboratory Medicine, Seoul National University Hospital, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 03080, Korea
E-mail: mwseong@snu.ac.kr
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Thalassemia is characterized by the impaired synthesis of globin chains due to disease-causing variants in α- or β-globin genes. In this review, we provide an overview of the molecular basis underlying α- and β-thalassemia, and of the current technologies used to characterize these disease-causing variants for the diagnosis of thalassemia. Understanding these molecular basis and technologies will prove to be beneficial for the accurate diagnosis of thalassemia.
Keywords Thalassemia, α-globin gene, β-globin gene
Blood Res 2021; 56(S1): S39-S43
Published online April 30, 2021 https://doi.org/10.5045/br.2021.2020332
Copyright © The Korean Society of Hematology.
Jee-Soo Lee, Sung Im Cho, Sung Sup Park, Moon-Woo Seong
Department of Laboratory Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
Correspondence to:Moon-Woo Seong, M.D., Ph.D.
Department of Laboratory Medicine, Seoul National University Hospital, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 03080, Korea
E-mail: mwseong@snu.ac.kr
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Thalassemia is characterized by the impaired synthesis of globin chains due to disease-causing variants in α- or β-globin genes. In this review, we provide an overview of the molecular basis underlying α- and β-thalassemia, and of the current technologies used to characterize these disease-causing variants for the diagnosis of thalassemia. Understanding these molecular basis and technologies will prove to be beneficial for the accurate diagnosis of thalassemia.
Keywords: Thalassemia, α-globin gene, β-globin gene
Table 1 . Common variants of each variant type of α-thalassemia..
Gene | Variant type | Common variant | Effect |
---|---|---|---|
α-globin gene | --/ | --SEA, --MED, --FIL | α0 |
-α/ | -α3.7 and -α4.2 | α+ | |
αTα/ | αIVS1(-5nt)α, αPA(AATAAG)α, αCSα | α+ | |
ααT/ | α+ |
Table 2 . Distribution of α-thalassemia genotypes identified in Seoul National University Hospital (South Korea)..
α-thalassemia genotypes | N | % |
---|---|---|
--SEA/αα | 8 | 33.3 |
α3.7/αα | 5 | 20.8 |
--SEA/α3.7 | 4 | 16.7 |
α3.7/α3.7 | 2 | 8.3 |
α3.7/α212 patchwork | 2 | 8.3 |
--/αα (ATRA-16 syndrome) | 1 | 4.2 |
αα/αα (HS-40 deletion) | 1 | 4.2 |
--SEA/-α4.2 | 1 | 4.2 |
Total | 24 |
Table 3 . Types of variants in β-thalassemia..
Gene | Variant type | Effect |
---|---|---|
β-globin gene | Transcriptional variants | β+ or β++ |
Primary RNA transcript processing | β0, β+, or β++ | |
3’ UTR or poly-A site | β+ | |
Translation | ||
Initiation codon | β0 | |
Premature termination codon | β0 |
Abbreviation: UTR, untranslated region..
Table 4 . Molecular spectrum of β-thalassemia identified in Seoul National University Hospital (South Korea)..
HGVS nomenclature | Amino acid change | N of alleles | % |
---|---|---|---|
c.-138C>A | 1 | 0.6 | |
c.-81A>G | 2 | 1.2 | |
c.79G>A | p.Glu27Lys | 18 | 11.0 |
c.92G>A | p.Arg31Lys | 1 | 0.6 |
c.92+1G>A | 2 | 1.2 | |
c.92+1G>T | 2 | 1.2 | |
c.92+2T>C | 1 | 0.6 | |
c.92+5G>C | 3 | 1.8 | |
c.93-21G>A | 3 | 1.8 | |
c.93-1G>C | 2 | 1.2 | |
c.315+1G>A | 12 | 7.4 | |
c.316-197C>T | 1 | 0.6 | |
c.316-2A>G | 1 | 0.6 | |
c.1A>G | Start loss | 2 | 1.2 |
c.2T>G | start loss | 25 | 15.3 |
c.48G>A | p.Trp16* | 6 | 3.7 |
c.52A>T | p.Lys18* | 18 | 11.0 |
c.114G>A | p.Trp38* | 4 | 2.5 |
c.118C>T | p.Gln40* | 1 | 0.6 |
c.364G>T | p.Glu122* | 13 | 8.0 |
c.394C>T | p.Gln132* | 1 | 0.6 |
c.25_26del | p.Lys9Valfs*14 | 1 | 0.6 |
c.27dup | p.Ser10Valfs*14 | 8 | 4.9 |
c.126_129del | p.Phe42Leufs*19 | 15 | 9.2 |
c.201del | p.Val68Cysfs*22 | 1 | 0.6 |
c.217dup | p.Ser72Lysfs*2 | 2 | 1.2 |
c.253_254del | p.Thr85Leufs*6 | 1 | 0.6 |
c.270_271del | p.Ser90Argfs*5 | 2 | 1.2 |
c.287dup | p.Leu97Alafs*6 | 1 | 0.6 |
c.378_379del | p.Val127Alafs*13 | 1 | 0.6 |
c.182T>A | p.Val61Glu | 1 | 0.6 |
c.383A>G | p.Gln128Arg | 2 | 1.2 |
7 | 4.3 | ||
Beta-globin gene cluster deletion | 1 | 0.6 | |
1 | 0.6 | ||
Total | 163 |
Table 5 . Molecular diagnostic methods for thalassemia..
Mutation type | Method |
---|---|
Deletion | Gap PCR |
MLPAa,b) | |
Non-deletion | Allele-specific PCR |
Reverse dot blotting | |
Denaturing gradient gel electrophoresis | |
ARMS | |
Sanger sequencinga) | |
Next-generation sequencinga) |
a)Methods currently applied in clinical laboratories in Korea. b)Commercial kits available [SALSA MLPA Probemix P140 and P102 (MRC-Holland, Amsterdam, The Netherlands)]..
Abbreviations: ARMS, amplification refractory mutation system; MLPA, multiplex ligation-dependent probe amplification; PCR, polymerase chain reaction..
Young Kyung Lee, Hee-Jin Kim, Kyunghoon Lee, Sang Hyuk Park, Sang Hoon Song, Moon-Woo Seong, Myungshin Kim, and Jin Yeong Han
Blood Res 2019; 54(1): 17-22Seyed Ali Mohammad Arabzadeh, Farideh Alizadeh, Ahmad Tavakoli, Hamidreza Mollaei, Farah Bokharaei-Salim, Gharib Karimi, Mohammad Farahmand, Helya Sadat Mortazavi, and Seyed Hamidreza Monavari
Blood Res 2017; 52(1): 50-54Eun Sil Park, Hye Lim Jung, Hee-Jin Kim, Sung Sup Park, Soon Hwan Bae, Hee Young Shin, Sang Hoon Song, Kyung-Nam Koh, Chuhl Joo Lyu, Young Tak Lim, Dong Kyun Han, and Jeong Ok Hah
Blood Res 2013; 48(3): 211-216